Dose reduced conditioning and allogeneic stem cell transplantation in 36 patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Bornhäuser, M
Schaich, M
Schaekel, U
Mahlberg, R
Clemens, M
Ehninger, G
机构：
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [21] Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    Kröger, N
    Shimoni, A
    Zabelina, T
    Schieder, H
    Panse, J
    Ayuk, F
    Wolschke, C
    Renges, H
    Dahlke, J
    Atanackovic, D
    Nagler, A
    Zander, A
    [J]. BONE MARROW TRANSPLANTATION, 2006, 37 (04) : 339 - 344
  • [22] Impact of disease burden at time of allogeneic stem cell transplantation (SCT) in adults with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
    Kebriaei, P
    Kline, J
    Kasza, K
    Stock, W
    Larson, RA
    van Besien, K
    [J]. BLOOD, 2003, 102 (11) : 725A - 725A
  • [23] Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    N. Kröger
    M. Bornhäuser
    G. Ehninger
    R. Schwerdtfeger
    H. Biersack
    H. G. Sayer
    H. Wandt
    K. Schäfer-Eckardt
    J. Beyer
    M. Kiehl
    A. R. Zander
    [J]. Annals of Hematology, 2003, 82 : 336 - 342
  • [24] Sequential Treatment with Chemotherapy and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Fanconi Anemia Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Talbot, Alexis
    de Latour, Regis Peffault
    Buchbinder, Nimrod
    Tabrizi, Reza
    Lengline, Etienne
    Vigouroux, Stephane
    Milpied, Noel
    Michallet, Mauricette
    Socie, Gerard
    [J]. BLOOD, 2012, 120 (21)
  • [25] Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    Kröger, N
    Bornhäuser, M
    Ehninger, G
    Schwerdtfeger, R
    Biersack, H
    Sayer, HG
    Wandt, H
    Schäfer-Eckardt, K
    Beyer, J
    Kiehl, M
    Zander, AR
    [J]. ANNALS OF HEMATOLOGY, 2003, 82 (06) : 336 - 342
  • [26] Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia
    Horwitz, Mitchell E.
    [J]. CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) : 197 - 202
  • [27] OUTCOME OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) WITH ADVERSE CYTOGENETICS
    Gorcea, C. Monica
    Lobetti-Bodoni, C.
    Dignan, F.
    Woodward, J.
    Waller, M.
    Tholouli, E.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 : S107 - S107
  • [28] GM-CSF secreting leukemia cell vaccinations after allogeneic reduced intensity peripheral blood stem cell transplantation (SCT) for advanced myelodysplastic syndrome (MDS) or refractory acute myeloid leukemia (AML).
    Ho, Vincent
    Dranoff, Glenn
    Kim, Haesook
    Pasek, Mildred
    Cutler, Corey
    Alyea, Edwin
    Koreth, John
    Antin, Joseph H.
    Soiffer, Robert J.
    [J]. BLOOD, 2006, 108 (11) : 1052A - 1052A
  • [29] Fludrabine Treosulfan Conditioning Regimen Appears Safe and Effective in Patients with Acute Myeloid Leukemia(AML) and Myelodysplastic Syndrome (MDS) Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
    Yadav, Chitresh
    Damodar, Sharat
    Bhargava, Rahul
    Haridas, Nikhil Krishna
    Jaishetwar, Ganesh S.
    Paul, Mobin
    Ram, Bharath S.
    Nayak, Akshatha
    Harimadhavan, Monisha
    Mangal, Rohit
    Unni, Manoj
    Ganapathy, Rema
    Yawalkar, Rashmi Suresh
    Agrawal, Shreya Gopal
    Mony, Ullas
    Kartha, Nivedhitha
    Sidharthan, Neeraj
    [J]. BLOOD, 2022, 140 : 12816 - 12818
  • [30] Duration to engraftment requires significantly much more time in myelodysplastic syndrome (MDS) patients as compared to acute myeloid leukemia (AML) patients following allogeneic stem cell transplantation.
    Bitan, M
    Shapira, MY
    Resnick, IB
    Gesundheit, B
    Zilberman, I
    Ackerstein, A
    Samuel, S
    Elad, S
    Slavin, S
    Or, R
    [J]. BLOOD, 2005, 106 (11) : 416B - 417B
12345